Skip to Content

Janus Henderson Global Life Sciences T JAGLX

Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 74.52  /  +0.59 %
  • Total Assets 5.0 Bil
  • Adj. Expense Ratio
    0.920%
  • Expense Ratio 0.920%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.07%
  • Turnover 34%

USD | NAV as of Feb 23, 2024 | 1-Day Return as of Feb 23, 2024, 11:34 PM GMT+0

Morningstar’s Analysis JAGLX

Will JAGLX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Janus Henderson Global Life Sciences T's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JAGLX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 35.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

UnitedHealth Group Inc

6.45 317.3 Mil
Healthcare

Eli Lilly and Co

5.12 251.8 Mil
Healthcare

Novo Nordisk A/S Class B

4.21 207.1 Mil
Healthcare

AstraZeneca PLC

3.96 194.9 Mil
Healthcare

Merck & Co Inc

3.11 153.3 Mil
Healthcare

Sanofi SA

2.66 130.8 Mil
Healthcare

Abbott Laboratories

2.65 130.3 Mil
Healthcare

AbbVie Inc

2.60 128.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.35 115.7 Mil
Healthcare

Novartis AG ADR

2.32 114.4 Mil
Healthcare